Clinical Trial: Efficacy and safety of tofacitinib at different doses in the treatment of adult moderate-to-severe prurigo nodularis: a prospective, randomized, open-label, blinded endpoint exploratory clinical study (China)

Posted On: 2026-11-02

China, Nov. 2 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and safety of tofacitinib at different doses in the treatment of adult moderate-to-severe prurigo nodularis: a prospective, randomized, open-label, blinded endpoint exploratory clinical study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135686

Registration Time: 2026/11/01

Type: Interventional study

Primary Sponsor: The First Affiliated Hospital of Army Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=349893

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया हमे संपर्क करें.

विशेष

Category

Source

Publication

Location

Clinical Trial: Efficacy and safety of tofacitinib at different doses in the treatment of adult moderate-to-severe prurigo nodularis: a prospective, randomized, open-label, blinded endpoint exploratory clinical study (China)